Abstract: The disclosure provides a work vehicle. The work vehicle includes: a frame, a wheel unit connected with the frame, a working unit connected with the frame, and a power source arranged on the frame to supply power. The work vehicle further includes: a brake assembly connected with the wheel unit, a locking assembly, provided with a lock arm to lock the brake assembly, and a starting mechanism. The starting mechanism includes a starting arm connected with the lock arm to drive the lock arm to move when the starting arm is operated to unlock the brake assembly.

Abstract: Anti-reflective assemblies comprise: a high dielectric permittivity substrate comprising a ceramic and a nonporous multilayer anti-reflective film contacting or adhesively bonded to the substrate. The nonporous multilayer anti-reflective film comprises sequential first, second, and third layers of sequentially decreasing dielectric permittivity. Each layer comprises a respective polymer matrix and filler particles.

Abstract: A mower includes a frame, a walking assembly, a cutting deck assembly and an operating mechanism. The walking assembly, the cutting deck assembly and the operating mechanism are all installed on the frame, and the operating mechanism is configured to control a walking of the walking assembly. The operating mechanism includes an operating lever mounting base, an operating lever, a limiting assembly and a reset assembly. The operating lever mounting base is rotatably installed on the frame along a first direction. The operating lever is rotatably installed on the operating lever mounting base along a second direction. The reset assembly drives the operating lever to reset to an initial position in the first direction, and the limiting assembly locks the operating lever in the initial position.

Abstract: A composition having clevidipine as an active ingredient is described. The composition includes clevidipine as an active ingredient and an amount of the impurity H168/79 that is no greater than about 1.5%, or where the ratio between clevidipine and H168/79 is equal or above 60 to 1.

Abstract: A mower includes a frame, a cutting deck assembly and a walking mechanism. The cutting deck assembly is mounted on the frame. The walking mechanism is mounted on the frame and includes a front wheel assembly and a rear wheel assembly. The frame includes a front frame and a rear frame. The front frame is detachably connected with the rear frame. The front frame is provided with the front wheel assembly, and the rear frame is provided with the rear wheel assembly. When the cutting deck assembly needs to be replaced to meet use requirements, the front frame and the rear frame of appropriate specifications are first selected to be fixed to ensure that the cutting deck assembly has a suitable mounting size, so that the suitable cutting deck assembly may be replaced in different working environments to meet the use requirements of a variety of environments.

Abstract: Use of an exosome derived from decidual natural killer (dNK) cells or a dNK cell subset in the preparation of a drug and an auxiliary therapeutic agent for infertility-related diseases is provided. Experiments have confirmed that the exosome treats the endometrial growth disorder-related diseases by promoting increase of endometrial thickness, increasing endometrial cell viability, reducing endometrial cell damage, promoting VEGF expression, and maintaining stemness and stimulating proliferation of endometrial stromal cells, such that a conception rate for endometrial injury model mice increases from 20% to 50%-70%; and the exosome treats the maternal-fetal immune tolerance disorder-related diseases by exerting immune tolerance, reducing a spontaneous abortion rate, and increasing a helper T cell level.

Abstract: Anti-reflective assemblies comprise: a high dielectric permittivity substrate comprising a ceramic and a nonporous multilayer anti-reflective film contacting or adhesively bonded to the substrate. The nonporous multilayer anti-reflective film comprises sequential first, second, and third layers of sequentially decreasing dielectric permittivity. Each layer comprises a respective polymer matrix and filler particles.

Abstract: Disclosed are compounds of Formula (I): or a salt thereof, wherein: X is CR6 or N; Y is CR3 or N; R1, R2, R3, R4, R5, R6, R7, and m are defined herein. Also disclosed are methods of using such compounds to inhibit the activity of one or both of diacylglycerol kinase alpha (DGK?) and diacylglycerol kinase zeta (DGK?), and pharmaceutical compositions comprising such compounds. These compounds are useful in the treatment of viral infections and proliferative disorders, such as cancer.

Abstract: The disclosure provides a mower. The mower includes a vehicle frame, a walking assembly, a working assembly, a seat and a battery pack. The walking assembly includes a first walking wheel assembly and a second walking wheel assembly connected with the vehicle frame. The first walking wheel assembly and/or the second walking wheel assembly includes a main walking wheel and a hub motor, the main walking wheel is connected with the hub motor, and the hub motor is arranged outside a side of the vehicle frame. The working assembly is connected with the vehicle frame. The seat is arranged on the vehicle frame. The battery pack is lowered and mounted on the vehicle frame and extends below the seat.

Abstract: Disclosed are compounds of Formula (I): or a salt thereof, wherein: R1, R2, R3, and R4 are defined herein. Also disclosed are methods of using such compounds to inhibit the activity of one or both of diacylglycerol kinase alpha (DGK ?) and diacylglycerol kinase zeta (DGK?), and pharmaceutical compositions comprising such compounds. These compounds are useful in the treatment of viral infections and proliferative disorders, such as cancer.

Abstract: Pharmaceutical compositions, and a method of stabilizing pharmaceutical compositions having clevidipine, or any pharmaceutically acceptable salt thereof, as the active ingredient is described. The method includes the slowing down or inhibiting of the oxidation pathway of clevidipine. This can be accomplished by reducing the amount the pharmaceutical composition is exposed to oxygen and/or light during the manufacturing and storing processes. According to this method, oxygen must be removed or replaced, or light must be sufficiently blocked such that light energy cannot reach the active ingredient of the composition, or is reduced to a level that the light-induced oxidation reaction converting clevidipine to H324/78 is minimized, such that the total detectable level of H324/78 in a given composition sample does not exceed about 0.2% on a weight-by-weight basis, or the ratio of clevidipine to H324/78 is equal to or greater than about 450 to 1 on a weight-to-weight basis.

Abstract: Disclosed are compounds of Formula (I): or a salt thereof, wherein: R1, R2, R3, R4, R5, and m are defined herein. Also disclosed are methods of using such compounds to inhibit the activity of one or both of diacylglycerol kinase alpha (DGK?) and diacylglycerol kinase zeta (DGK?), and pharmaceutical compositions comprising such compounds. These compounds are useful in the treatment of viral infections and proliferative disorders, such as cancer.

Abstract: Provided are inhibitors of diacylglycerol kinases (DGK) and methods for treating diseases that would benefit from the stimulation of the immune system, such as cancer and infections diseases, comprising administering a DGK inhibitor in combination with an antagonist of the PD 1/PD-L 1 axis and/or an antagonist of CTLA4.

Abstract: Disclosed are compounds of Formula (I) or a salt thereof, wherein: R1, R2, R3, R4, R5, R6, and m are defined herein. Also disclosed are methods of using such compounds to inhibit the activity of one or both of diacylglycerol kinase alpha (DGK?) and diacylglycerol kinase zeta (DGK?), and pharmaceutical compositions comprising such compounds. These compounds are useful in the treatment of viral infections and proliferative disorders, such as cancer.

Abstract: Disclosed are compounds of Formula (I): or a salt thereof, wherein: R1, R2, R3, R4, R5, and m are defined herein. Also disclosed are methods of using such compounds to inhibit the activity of one or both of diacylglycerol kinase alpha (DGK?) and diacylglycerol kinase zeta (DGK?), and pharmaceutical compositions comprising such compounds. These compounds are useful in the treatment of viral infections and proliferative disorders, such as cancer.

Abstract: A soluble dimeric immunoadhesin includes a dimerized first polypeptide chain and a dimerized second polypeptide chain. The first polypeptide chain has a general formula of Z1-Z2, and the second polypeptide chain has a general formula of Y1-Y2. Z1 is (i) an extracellular domain of a first cell surface receptor or a functional variant or fragment thereof, or (ii) a first cytokine or a functional variant or fragment thereof; Z2 is a dimerization domain of an immunoglobulin constant region or a functional variant or fragment thereof. Y1 is an extracellular domain of a second cell surface receptor or a functional variant or fragment thereof, or (ii) a second cytokine or a functional variant or fragment thereof. Y2 is a dimerization domain of an immunoglobulin constant region or a functional variant or fragment thereof. A dimeric protein can be used for the treatment and prevention of infertility-related diseases.

Abstract: The disclosure provides a work vehicle. The work vehicle includes: a frame, a wheel unit connected with the frame, a working unit connected with the frame, and a power source arranged on the frame to supply power. The work vehicle further includes: a brake assembly connected with the wheel unit, a locking assembly, provided with a lock arm to lock the brake assembly, and a starting mechanism. The starting mechanism includes a starting arm connected with the lock arm to drive the lock arm to move when the starting arm is operated to unlock the brake assembly.

Abstract: Use of an exosome derived from decidual natural killer (dNK) cells or a dNK cell subset in the preparation of a drug and an auxiliary therapeutic agent for infertility-related diseases is provided. Experiments have confirmed that the exosome treats the endometrial growth disorder-related diseases by promoting increase of endometrial thickness, increasing endometrial cell viability, reducing endometrial cell damage, promoting VEGF expression, and maintaining stemness and stimulating proliferation of endometrial stromal cells, such that a conception rate for endometrial injury model mice increases from 20% to 50%-70%; and the exosome treats the maternal-fetal immune tolerance disorder-related diseases by exerting immune tolerance, reducing a spontaneous abortion rate, and increasing a helper T cell level.

Abstract: A composition having clevidipine as an active ingredient is described. The composition includes clevidipine as an active ingredient and an amount of the impurity H168/79 that is no greater than about 1.5%, or where the ratio between clevidipine and H168/79 is equal or above 60 to 1.

Abstract: Disclosed are compounds of Formula (I): or a salt thereof, wherein: R1, R2, R3, and R4 are defined herein. Also disclosed are methods of using such compounds to inhibit the activity of one or both of diacylglycerol kinase alpha (DGK ?) and diacylglycerol kinase zeta (DGK?), and pharmaceutical compositions comprising such compounds. These compounds are useful in the treatment of viral infections and proliferative disorders, such as cancer.